熱門資訊> 正文

XTL生物制药收到纳斯达克出价不足通知

2025-12-25 05:33

Xtl生物製藥(XTLB) 0

XTL Biopharmaceuticals (XTLB) received a Nasdaq notice dated December 22, 2025, for failing to maintain the $1 minimum bid price requirement.
The deficiency is based on the company’s ADS closing bid price being below $1 for 30 consecutive business days.
XTL has a 180-day compliance period, ending June 22, 2026, to regain compliance.

More on XTL Biopharmaceuticals

Seeking Alpha’s Quant Rating on XTL Biopharmaceuticals
Financial information for XTL Biopharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。